POSEIDA THERAPEUTICS INC's ticker is PSTX and the CUSIP is 73730P108. A total of 86 filers reported holding POSEIDA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,220,500 | +35.2% | 5,975,000 | 0.0% | 0.08% | +4.1% |
| Q2 2023 | $10,516,000 | -42.9% | 5,975,000 | 0.0% | 0.07% | -59.0% |
| Q1 2023 | $18,403,000 | -41.9% | 5,975,000 | 0.0% | 0.18% | -68.0% |
| Q4 2022 | $31,667,500 | +50.1% | 5,975,000 | 0.0% | 0.56% | +135.6% |
| Q3 2022 | $21,092,000 | +64.6% | 5,975,000 | +20.3% | 0.24% | +56.3% |
| Q2 2022 | $12,815,000 | -42.4% | 4,967,227 | 0.0% | 0.15% | -43.2% |
| Q1 2022 | $22,253,000 | -34.2% | 4,967,227 | 0.0% | 0.27% | -27.7% |
| Q4 2021 | $33,827,000 | -6.6% | 4,967,227 | 0.0% | 0.37% | 0.0% |
| Q3 2021 | $36,211,000 | -27.2% | 4,967,227 | 0.0% | 0.37% | -10.5% |
| Q2 2021 | $49,772,000 | +4.9% | 4,967,227 | 0.0% | 0.41% | -9.3% |
| Q1 2021 | $47,437,000 | -12.9% | 4,967,227 | 0.0% | 0.45% | -31.2% |
| Q4 2020 | $54,490,000 | +25.9% | 4,967,227 | +1.8% | 0.66% | +17.5% |
| Q3 2020 | $43,281,000 | – | 4,879,490 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,043,267 | $7,605,000 | 1.52% |
| Privium Fund Management (UK) Ltd | 48,470 | $353,000 | 0.38% |
| Pentwater Capital Management LP | 4,967,227 | $36,211,000 | 0.37% |
| J. Goldman & Co LP | 301,391 | $2,197,000 | 0.11% |
| Perceptive Advisors | 787,745 | $5,743,000 | 0.08% |
| KNOTT DAVID M | 29,566 | $216,000 | 0.08% |
| Virtus ETF Advisers LLC | 23,082 | $168,000 | 0.07% |
| Altium Capital Management LP | 32,238 | $235,000 | 0.06% |
| Advisory Services Network, LLC | 268,290 | $1,956,000 | 0.06% |
| MCF Advisors LLC | 66,185 | $482,000 | 0.05% |